Drug Details
General Information of the Drug (ID: DR4000) | ||||
---|---|---|---|---|
Name |
Marbofloxacin
|
|||
Synonyms |
Marbofloxacin; 115550-35-1; Zeniquin; Marbocyl; UNII-8X09WU898T; 8X09WU898T; MFCD00864820; 7H-Pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; NCGC00166310-01; DSSTox_CID_26600; DSSTox_RID_81755; DSSTox_GSID_46600; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-3,7-dihydro-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid; Marbofloxacine [INN-French]; Marbofloxacinum [INN-Latin]; 9-Fluoro-3,7-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic Acid; Marbofloxacino [INN-Spanish]; CAS-115550-35-1; Marbofloxacin [INN:BAN]; Marbofloxacine/; CCRIS 8212; 9-Fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; PubChem16145; Marbofloxacin (USP/INN); Oprea1_079403; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid; cc-422; SCHEMBL134860; CHEMBL478120; DTXSID4046600; CHEBI:94723; EX-A015; ZINC537947; HY-B0126; RKL10084; Tox21_112406; ABP000382; ANW-42471; s1464; AKOS015853291; Tox21_112406_1; BCP9000896; CCG-229989; CS-1892; DB11426; GS-3323; NCGC00166310-02; NCGC00166310-03; 7H-Pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylic acid, 2,3-dihydro-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-; 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-piperazino)-7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid; AC-24289; AK327608; AB0105713; DB-041275; FT-0628168; M2240; D08156; AB01566820_01; 550M351; Marbofloxacin, VETRANAL(TM), analytical standard; Q909359; SR-01000772975; Q-201338; SR-01000772975-2; Marbofloxacin, European Pharmacopoeia (EP) Reference Standard; Marbofloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2- diazatricyclo[7.3.1.0^5,13^]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid; 7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1,2-diazatricyclo[7.3.1.0^{5,13}]trideca-5,7,9(13),11-tetraene-11-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl -1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid; 9-fluoro-2,3-dihydro-3-methyl-10-(4-methylpiperazin-1-yl)- 7-oxo-7H-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Chronic obstructive pulmonary disease [ICD-11: CA22] | Investigative | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C17H19FN4O4
|
|||
PubChem CID | ||||
Canonical SMILES |
CN1CCN(CC1)C2=C(C=C3C4=C2OCN(N4C=C(C3=O)C(=O)O)C)F
|
|||
InChI |
1S/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25)
|
|||
InChIKey |
BPFYOAJNDMUVBL-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 115550-35-1
|
|||
ChEBI ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Methyl gallate | Givotia rottleriformis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Salmonella Typhimurium in rats were used in this study. | |||||
Experimental
Result(s) |
MG has shown to increase the antimicrobial activity of MAR in vitro and ex vivo experiments without affecting the pharmacokinetics of MAR in rats. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | ERK activator kinase 1 (MEK1) | Molecule Info | [3] | |
KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | cGMP-PKG signaling pathway | |||
6 | cAMP signaling pathway | |||
7 | Chemokine signaling pathway | |||
8 | HIF-1 signaling pathway | |||
9 | FoxO signaling pathway | |||
10 | Sphingolipid signaling pathway | |||
11 | Oocyte meiosis | |||
12 | PI3K-Akt signaling pathway | |||
13 | Vascular smooth muscle contraction | |||
14 | Dorso-ventral axis formation | |||
15 | VEGF signaling pathway | |||
16 | Osteoclast differentiation | |||
17 | Focal adhesion | |||
18 | Gap junction | |||
19 | Signaling pathways regulating pluripotency of stem cells | |||
20 | Toll-like receptor signaling pathway | |||
21 | Natural killer cell mediated cytotoxicity | |||
22 | T cell receptor signaling pathway | |||
23 | B cell receptor signaling pathway | |||
24 | Fc epsilon RI signaling pathway | |||
25 | Fc gamma R-mediated phagocytosis | |||
26 | TNF signaling pathway | |||
27 | Long-term potentiation | |||
28 | Neurotrophin signaling pathway | |||
29 | Cholinergic synapse | |||
30 | Serotonergic synapse | |||
31 | Long-term depression | |||
32 | Regulation of actin cytoskeleton | |||
33 | Insulin signaling pathway | |||
34 | GnRH signaling pathway | |||
35 | Progesterone-mediated oocyte maturation | |||
36 | Estrogen signaling pathway | |||
37 | Melanogenesis | |||
38 | Prolactin signaling pathway | |||
39 | Thyroid hormone signaling pathway | |||
40 | Oxytocin signaling pathway | |||
41 | Prion diseases | |||
42 | Alcoholism | |||
43 | Hepatitis B | |||
44 | Influenza A | |||
45 | Pathways in cancer | |||
46 | Proteoglycans in cancer | |||
47 | MicroRNAs in cancer | |||
48 | Colorectal cancer | |||
49 | Renal cell carcinoma | |||
50 | Pancreatic cancer | |||
51 | Endometrial cancer | |||
52 | Glioma | |||
53 | Prostate cancer | |||
54 | Thyroid cancer | |||
55 | Melanoma | |||
56 | Bladder cancer | |||
57 | Chronic myeloid leukemia | |||
58 | Acute myeloid leukemia | |||
59 | Non-small cell lung cancer | |||
60 | Central carbon metabolism in cancer | |||
61 | Choline metabolism in cancer | |||
NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
2 | TGF_beta_Receptor Signaling Pathway | |||
Panther Pathway | Angiogenesis | Click to Show/Hide | ||
2 | B cell activation | |||
3 | EGF receptor signaling pathway | |||
4 | Endothelin signaling pathway | |||
5 | FGF signaling pathway | |||
6 | Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | |||
7 | Integrin signalling pathway | |||
8 | PDGF signaling pathway | |||
9 | T cell activation | |||
10 | Toll receptor signaling pathway | |||
11 | VEGF signaling pathway | |||
12 | Ras Pathway | |||
13 | Angiotensin II-stimulated signaling through G proteins and beta-arrestin | |||
14 | CCKR signaling map ST | |||
Pathwhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | Click to Show/Hide | ||
2 | Insulin Signalling | |||
Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | Click to Show/Hide | ||
2 | Endothelins | |||
3 | BCR signaling pathway | |||
4 | GMCSF-mediated signaling events | |||
5 | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||
6 | EPHB forward signaling | |||
7 | SHP2 signaling | |||
8 | Netrin-mediated signaling events | |||
9 | mTOR signaling pathway | |||
10 | Class IB PI3K non-lipid kinase events | |||
11 | IL2-mediated signaling events | |||
12 | Ras signaling in the CD4+ TCR pathway | |||
13 | Ceramide signaling pathway | |||
14 | IFN-gamma pathway | |||
15 | ErbB1 downstream signaling | |||
16 | ErbB2/ErbB3 signaling events | |||
17 | FOXM1 transcription factor network | |||
18 | PDGFR-beta signaling pathway | |||
19 | Neurotrophic factor-mediated Trk receptor signaling | |||
20 | Nongenotropic Androgen signaling | |||
21 | Hedgehog signaling events mediated by Gli proteins | |||
22 | CXCR3-mediated signaling events | |||
23 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
24 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
25 | Cellular roles of Anthrax toxin | |||
26 | Trk receptor signaling mediated by the MAPK pathway | |||
27 | Downstream signaling in naï | |||
28 | ||||
29 | Signaling events mediated by focal adhesion kinase | |||
Reactome | MAPK3 (ERK1) activation | Click to Show/Hide | ||
2 | Uptake and function of anthrax toxins | |||
3 | RAF activation | |||
4 | MAP2K and MAPK activation | |||
5 | Negative feedback regulation of MAPK pathway | |||
6 | MAP3K8 (TPL2)-dependent MAPK1/3 activation | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
3 | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
4 | Serotonin HTR1 Group and FOS Pathway | |||
5 | Estrogen signaling pathway | |||
6 | TCR Signaling Pathway | |||
7 | ErbB Signaling Pathway | |||
8 | Hypothetical Network for Drug Addiction | |||
9 | Senescence and Autophagy in Cancer | |||
10 | EPO Receptor Signaling | |||
11 | Regulation of Actin Cytoskeleton | |||
12 | IL-2 Signaling Pathway | |||
13 | Insulin Signaling | |||
14 | EGF/EGFR Signaling Pathway | |||
15 | MAPK Cascade | |||
16 | MAPK Signaling Pathway | |||
17 | TGF beta Signaling Pathway | |||
18 | IL-6 signaling pathway | |||
19 | Signaling of Hepatocyte Growth Factor Receptor | |||
20 | Focal Adhesion | |||
21 | Kit receptor signaling pathway | |||
22 | IL-3 Signaling Pathway | |||
23 | Bladder Cancer | |||
24 | Cardiac Hypertrophic Response | |||
25 | MAP kinase activation in TLR cascade | |||
26 | RAF/MAP kinase cascade | |||
27 | Nanoparticle-mediated activation of receptor signaling | |||
28 | Structural Pathway of Interleukin 1 (IL-1) | |||
29 | Genes and (Common) Pathways Underlying Drug Addiction | |||
30 | Nifedipine Activity | |||
31 | Aryl Hydrocarbon Receptor | |||
32 | PDGF Pathway | |||
33 | BDNF signaling pathway | |||
34 | Integrated Pancreatic Cancer Pathway | |||
35 | Oncostatin M Signaling Pathway | |||
36 | Corticotropin-releasing hormone | |||
37 | Interleukin-11 Signaling Pathway | |||
38 | AGE/RAGE pathway | |||
39 | B Cell Receptor Signaling Pathway | |||
40 | Prostate Cancer | |||
41 | Signaling Pathways in Glioblastoma | |||
42 | TSLP Signaling Pathway | |||
43 | IL-9 Signaling Pathway | |||
44 | Endothelin Pathways | |||
45 | IL-7 Signaling Pathway | |||
46 | Leptin signaling pathway | |||
47 | TSH signaling pathway | |||
48 | RANKL/RANK Signaling Pathway | |||
49 | IL-1 signaling pathway | |||
50 | Signaling by FGFR | |||
51 | Integrin-mediated Cell Adhesion | |||
52 | L1CAM interactions | |||
53 | MicroRNAs in cardiomyocyte hypertrophy | |||
54 | Regulation of toll-like receptor signaling pathway | |||
55 | Osteopontin Signaling | |||
56 | IL-5 Signaling Pathway |
